Company profile
NEWAMSTERDAM PHARMA CO N.V.
NASDAQ:NAMSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OBICETRAPIB | phase3 | — | 18 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (20)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06305559 | phase3 | active_not_recruiting | 2024-05-16 | 2027-11-01 | NewAmsterdam Pharma | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque |
| NCT05421078 | phase2 | completed | 2022-06-27 | 2023-03-24 | NewAmsterdam Pharma | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. |
| NCT06081166 | phase1 | completed | 2023-11-11 | 2023-12-02 | NewAmsterdam Pharma | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin |
| NCT06547359 | phase1 | completed | 2024-10-01 | 2024-11-12 | NewAmsterdam Pharma | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects |
| NCT07219602 | phase3 | active_not_recruiting | 2025-12-11 | 2028-03-01 | NewAmsterdam Pharma | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome |
FDA applications (0)
No records yet.